Add-on Acquisition • Life Science

XenoTherapeutics Acquires Repare Therapeutics

On November 14, 2025, XenoTherapeutics acquired life science company Repare Therapeutics

Acquisition Context

This is XenoTherapeutics’ 2nd transaction in the Life Science sector.
This is XenoTherapeutics’ 2nd transaction in Canada.
This is XenoTherapeutics’ 1st transaction in Quebec.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	November 14, 2025
Target	Repare Therapeutics
Sector	Life Science
Buyer(s)	XenoTherapeutics
Deal Type	Add-on Acquisition
Advisor(s)	Leerink Partners (Financial) Cooley (Legal)

Target Company

Repare Therapeutics

Montreal, Quebec, Canada

Repare Therapeutics is a precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. Repare Therapeutics was founded in 2016 and is headquartered in Montreal, Quebec.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

XenoTherapeutics

Boston, Massachusetts, United States

Category	Company
Founded	1996
Sector	Life Science
Employees	316
Revenue	9M USD (2022)

DESCRIPTION

XenoTherapeutics is a 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. XenoTherapeutics is based in Boston, Massachusetts.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
State: Quebec	1 of 1
Country: Canada	2 of 2
Year: 2025	2 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2025-07-14	ESSA Vancouver, British Columbia, Canada ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2025-07-14

ESSA

Vancouver, British Columbia, Canada

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Quebec M&A - Canada M&A - 2025 M&A